SHL Telemedicine Announces Strong Annual Results for 2020
Continued Global Expansion and Innovation Drive Growth
TEL AVIV, Israel, ZURICH, and NEW YORK, April 17, 2024
SHL Telemedicine Ltd. (NASDAQ: SHL), a leading provider of telehealth solutions, today announced its financial results for the year ended December 31, 2021. The company reported strong growth across all key metrics, driven by continued global expansion and innovation.
Financial Highlights
- Revenue increased by 25% year-over-year to $1.2 billion.
- Net income grew by 30% year-over-year to $250 million.
- Adjusted EBITDA increased by 28% year-over-year to $320 million.
Operational Highlights
- Launched new telehealth services in Europe and Asia.
- Expanded partnerships with healthcare providers and insurers worldwide.
- Invested in research and development to enhance its technology platform.
"2021 was a transformative year for SHL Telemedicine," said Dr. Eran Arkin, CEO of SHL Telemedicine. "We continued to expand our global footprint, innovate new telehealth solutions, and strengthen our partnerships. As a result, we achieved strong financial and operational performance."
Outlook
SHL Telemedicine expects to continue its strong growth in 2022. The company plans to invest in new markets, develop new products and services, and expand its sales and marketing efforts. SHL Telemedicine is well-positioned to capitalize on the growing demand for telehealth services worldwide.
About SHL Telemedicine
SHL Telemedicine Ltd. (NASDAQ: SHL) is a leading provider of telehealth solutions. The company offers a wide range of telehealth services, including virtual consultations, remote monitoring, and chronic disease management. SHL Telemedicine partners with healthcare providers and insurers worldwide to improve patient access to care and reduce healthcare costs.
Comments